Personalized Medicine, Availability, and Group Disparity: An Inquiry into How Physicians Perceive and Rate the Elements and Barriers of Personalized Medicine

被引:16
|
作者
Petersen, Katelin E. [1 ,2 ]
Prows, Cynthia A. [2 ,3 ]
Martin, Lisa J. [1 ,2 ]
Maglo, Koffi N. [4 ,5 ]
机构
[1] Univ Cincinnati, Sch Med, Dept Pediat, Cincinnati, OH 45221 USA
[2] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA
[3] Cincinnati Childrens Hosp Med Ctr, Patient Serv, Cincinnati, OH 45229 USA
[4] Univ Cincinnati, Dept Philosophy, Cincinnati, OH 45221 USA
[5] Univ Cincinnati, CCTST, Cincinnati, OH 45221 USA
关键词
Genetic testing; Health equality; Individualized healthcare; Perceptions; Personalized medicine; Pharmacogenomics; Race; GENOMIC MEDICINE; AFRICAN-AMERICAN; RESPONSE RATES; WARFARIN; RACE; PHARMACOGENETICS; DISEASE; HEALTH; CYP2C9; CARE;
D O I
10.1159/000362359
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: The success of personalized medicine depends on factors influencing the availability and implementation of its new tools to individualize clinical care. However, little is known about physicians' views of the availability of personalized medicine across racial/ethnic groups and the relationship between perceived availability and clinical implementation. This study examines physicians' perceptions of key elements/tools and potential barriers to personalized medicine in connection with their perceptions of the availability of the latter across subpopulations. Methods: Study subjects consisted of physicians recruited from Cincinnati Children's Hospital Medical Center and UC Health. An electronic survey conducted from September 2012 to November 2012 recruited 104 physicians. Wilcoxon rank sum analysis compared groups. Results: Physicians were divided about whether personalized medicine contributes to health equality, as 37.4% of them believe that personalized medicine is currently available only for some subpopulations. They also rated the importance of racial/ethnic background almost as high as the importance of genetic information in the delivery of personalized medicine. Actual elements of personalized medicine rated highest include family history, drug-drug interaction alerts in medical records, and biomarker measurements to guide therapy. Costs of gene-based therapies and genetic testing were rated the most significant barriers. The ratings of several elements and barriers were associated with perceived availability of personalized medicine across subpopulations. Conclusion: While physicians hold differing views about the availability and implementation of personalized medicine, they likewise establish complex relationships between race/ethnicity and personalized medicine that may carry serious implications for its clinical success. (C) 2014 S. Karger AG, Basel
引用
收藏
页码:209 / 220
页数:12
相关论文
共 41 条
  • [21] Personalized Medicine in Oncology in the Developing World: Barriers and Concepts to Improve Status Quo
    Adeniji, Adeoluwa Akeem
    Dulal, Soniya
    Martin, Mike G.
    WORLD JOURNAL OF ONCOLOGY, 2021, 12 (2-3) : 50 - 60
  • [22] The use of personalized medicine for patient selection for renal transplantation: Physicians' views on the clinical and ethical implications
    Marianne Dion-Labrie
    Marie-Chantal Fortin
    Marie-Josée Hébert
    Hubert Doucet
    BMC Medical Ethics, 11
  • [23] Pharmacogenomics, How to Deal with Different Types of Variants in Next Generation Sequencing Data in the Personalized Medicine Area
    Tafazoli, Alireza
    Wawrusiewicz-Kurylonek, Natalia
    Posmyk, Renata
    Miltyk, Wojciech
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (01) : 1 - 23
  • [24] How can the personal discovery process evolve personalized medicine? An interview with Laura Towart
    Towart, Laura A.
    PERSONALIZED MEDICINE, 2019, 16 (06) : 435 - 437
  • [25] Precision and Personalized Medicine: How Genomic Approach Improves the Management of Cardiovascular and Neurodegenerative Disease
    Strianese, Oriana
    Rizzo, Francesca
    Ciccarelli, Michele
    Galasso, Gennaro
    D'Agostino, Ylenia
    Salvati, Annamaria
    Del Giudice, Carmine
    Tesorio, Paola
    Rusciano, Maria Rosaria
    GENES, 2020, 11 (07) : 1 - 24
  • [26] Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application
    Lightbody, Gaye
    Haberland, Valeriia
    Browne, Fiona
    Taggart, Laura
    Zheng, Huiru
    Parkes, Eileen
    Blayney, Jaine K.
    BRIEFINGS IN BIOINFORMATICS, 2019, 20 (05) : 1795 - 1811
  • [27] Challenges and barriers for the adoption of personalized medicine in Europe: the case of Oncotype DX Breast Recurrence Score® test
    Horgan, Denis
    Hofman, Paul
    Giacomini, Patrizio
    Dube, France
    Singh, Jaya
    Schneider, Daniel
    Hills, Tanya
    Faikish, Jennifer
    van den Bulcke, Marc
    Malapelle, Umberto
    Gajewski, Maciej
    Subbiah, Vivek
    DIAGNOSIS, 2024,
  • [28] How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine
    Dunlop, Boadie W.
    McCabe, Bhrett
    Eudicone, James M.
    Sheehan, John J.
    Baker, Ross A.
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2014, 29 (06) : 528 - 536
  • [29] Barriers to Deliver Personalized Medicine to Young Patients With Non-Small Cell Lung Cancer in Latin America
    Fernandez, Liliana
    Henao, Juan F.
    Sua, Luz F.
    Zuniga, Valeria
    Gutierrez, Leidys
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S192 - S193
  • [30] VARIABLE SELECTION FOR QUALITATIVE INTERACTIONS IN PERSONALIZED MEDICINE WHILE CONTROLLING THE FAMILY-WISE ERROR RATE
    Gunter, Lacey
    Zhu, Ji
    Murphy, Susan
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2011, 21 (06) : 1063 - 1078